A few comments..
* Bronchitol works higher up the pathological cascade hence could replace the need for Pulmoyze and anti-biotics in some patient groups
* For adults over 6months, FEV1 under control (50ml bronchitol as compartor) is 4.88% improvement vs 4.68% improvement for baseline. I thought it would be 8%+ for adults from baseline?! Lombard et al - whats your take on this?
* ASM8 looks like a good prospect
* I wonder if mgt can put out data for 24months etc I wonder if it shows constant improvement
Ann: Investor Presentation , page-2
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
